Amgen Inc.

Kirin-amgen, Inc.

Amgen K-a, Inc.

Immunex Corporation

Jacques J Peschon

Joel E Tocker

James F Smothers

David Fitzpatrick

Christopher Mehlin

Ai Ching Lim

Kendall M Mohler

Dauphine S Barone

Mary K Kennedy

John D Pluenneke

Ching Lim Ai

The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.

IL-17 receptor A antigen binding proteins

IL-17 Receptor A antigen binding proteins

Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.

The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.

Methods of treating psoriasis using IL-17 receptor A antibodies

The present invention relates to IL-17 receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, and the polynucleotide sequences encoding them, as well as host cells, expression vectors, and methods of making IL-17 receptor A antigen binding proteins.

Polynucleotides encoding IL-17 receptor A antigen binding proteins

The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.

Methods of using IL-17 receptor a antibodies

Methods of treating psoriasis using IL-17 Receptor A antibodies

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&#x3b1; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&#x3b1; inhibitors.

Growing community of inventors

Seattle, WA, United States of America

Jacques J Peschon